Today’s Research Reports on Stocks to Watch: Atossa Genetics and Forward Pharma

Shares of Forward Pharma saw an explosive gain on Tuesday despite any significant news from the company yesterday. Shares of Atossa Genetics also saw significant gains on Tuesday after it was revealed on Monday that the company would be hosting a conference call this week to discuss preliminary results from its Phase 1 dose escalation study of its proprietary topical Endoxifen.

RDI Initiates Coverage on:

Forward Pharma A/S

Atossa Genetics Inc.

Forward Pharma shares were soaring in yesterday’s trading session, ending the day with a 35.28% gain. With an average volume of just about 50,000 shares, trading volume was significant on Tuesday with nearly 1.8 million shares traded. The Danish biopharmaceutical company announced roughly a week ago the filing in the U.S. Court of Appeals for the Federal Circuit of the opening brief for the appeal of the PTAB decision that ended the interference proceeding between the Forward 11/576,871 patent application and an issued Biogen patent. The company’s CEO Dr. Claus Bo Svendsen commented, "We continue to believe that our intellectual property is strong and that we have presented compelling arguments to have the PTAB interference decision reversed. Our appeal is progressing on schedule, and, along with the European ‘355 Opposition Proceeding, is the key focus of Forward Pharma.”

Access RDI’s Forward Pharma A/S Research Report at:

Atossa Genetics shares skyrocketed on Tuesday and closed the day up 30.68%. Trading volume was also considerably larger at nearly 13.5 million shares traded compared to an average volume of just under 500,000 shares. There was no significant news from the Atossa yesterday, but on Monday the clinical-stage pharmaceutical company that’s developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that it would be hosting a conference call on September 14, 2017 at 2 pm EDT. The call will discuss preliminary results from its Phase 1 dose escalation study of its proprietary topical Endoxifen, which is an active metabolite of the FDA-approved drug tamoxifen. Tamoxifen is currently used to treat breast cancer and for breast cancer prevention in high risk patients.

Access RDI’s Atossa Genetics Inc. Research Report at:

Our Actionable Research on Forward Pharma A/S (NASDAQ: FWP) and Atossa Genetics Inc. (NASDAQ: ATOS) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and reviewed by Nadia Noorani, CFA® charter holder. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.